Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

becton dickinson & co. - BDX

BDX

Close Chg Chg %
213.44 -1.58 -0.74%

Closed Market

211.86

-1.58 (0.74%)

Volume: 2.17M

Last Updated:

Nov 6, 2026, 3:59 PM EDT

Trade Now

Company Overview: becton dickinson & co. - BDX

BDX Key Data

Open

$210.99

 Day Range

209.11 - 214.88

52 Week Range

138.90 - 214.88

 Market Cap

$56.98B

Shares Outstanding

272.39M

 Public Float

271.83M

Beta

0.22

 Rev. Per Employee

N/A

P/E Ratio

63.10

 EPS

$4.15

Yield

196.68%

 Dividend

$1.06

EX-DIVIDEND DATE

Dec 10, 2026

 SHORT INTEREST

N/A

AVERAGE VOLUME

1.85M

  

BDX Performance

1 Week
 
 7.07%
 
1 Month
 
 15.31%
 
3 Months
 
 19.80%
 
1 Year
 
 49.86%
 
5 Years
 
 11.76%
 

BDX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 19
Full Ratings ➔

About becton dickinson & co. - BDX

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

BDX At a Glance

Becton, Dickinson & Co.
1 Becton Drive
Franklin Lakes, New Jersey 07417-1880
Phone 1-201-847-6800 Revenue 19.46B
Industry Medical Specialties Net Income 1.15B
Sector Health Technology Employees N/A
Fiscal Year-end 09 / 2027
View SEC Filings

BDX Valuation

P/E Current 63.096
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 43.763
Price to Sales Ratio 2.575
Price to Book Ratio N/A
Price to Cash Flow Ratio 14.89
Enterprise Value to EBITDA 12.347
Enterprise Value to Sales 3.363
Total Debt to Enterprise Value 0.25

BDX Efficiency

Revenue/Employee N/A
Income Per Employee N/A
Receivables Turnover 7.022
Total Asset Turnover 0.367

BDX Liquidity

Current Ratio 0.872
Quick Ratio 0.537
Cash Ratio 0.107

BDX Profitability

Gross Margin 47.356
Operating Margin 15.737
Pretax Margin 9.277
Net Margin 5.89
Return on Assets 2.671
Return on Equity 5.66
Return on Total Capital 3.454
Return on Invested Capital 3.464

BDX Capital Structure

Total Debt to Total Equity 66.222
Total Debt to Total Capital 39.84
Total Debt to Total Assets 32.181
Long-Term Debt to Equity 54.38
Long-Term Debt to Total Capital 32.715
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Becton Dickinson & Co. - BDX

Collapse All in section
All values USD millions. 2023 2024 2025 2026 5-year trend
Sales/Revenue
19.37B 20.18B 21.84B 19.46B
Sales Growth
+2.66% +4.16% +8.24% -10.91%
Cost of Goods Sold (COGS) incl D&A
11.20B 11.05B 11.91B 10.24B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
2.16B 2.14B 2.31B 2.24B
Depreciation
- 696.00M 676.00M 728.00M
Amortization of Intangibles
- 1.47B 1.47B 1.59B
COGS Growth
+7.78% -1.33% +7.80% -14.03%
Gross Income
8.17B 9.13B 9.93B 9.21B
Gross Income Growth
-3.62% +11.69% +8.77% -7.16%
Gross Profit Margin
+42.17% +45.22% +45.44% +47.36%
2023 2024 2025 2026 5-year trend
SG&A Expense
5.96B 6.05B 6.54B 5.95B
Research & Development
1.24B 1.19B 1.26B 988.00M
Other SG&A
4.73B 4.86B 5.28B 4.96B
SGA Growth
- +1.37% +8.20% -9.02%
Other Operating Expense
9.00M (9.00M) 2.00M 199.00M
Unusual Expense
339.00M 676.00M (5.00B) 806.00M
EBIT after Unusual Expense
1.86B 2.41B 8.38B 2.26B
Non Operating Income/Expense
257.00M 122.00M (5.89B) 113.00M
Non-Operating Interest Income
49.00M 163.00M 38.00M 27.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
452.00M 528.00M 613.00M 564.00M
Interest Expense Growth
+13.57% +16.81% +16.10% -7.99%
Gross Interest Expense
503.00M 585.00M 675.00M 564.00M
Interest Capitalized
- 51.00M 57.00M 62.00M
Pretax Income
1.66B 2.00B 1.88B 1.80B
Pretax Income Growth
-6.79% +20.64% -6.18% -4.04%
Pretax Margin
+8.58% +9.94% +8.61% +9.28%
Income Tax
132.00M 300.00M 203.00M 388.00M
Income Tax - Current - Domestic
- 451.00M 149.00M 207.00M
Income Tax - Current - Foreign
- 303.00M 362.00M 470.00M
Income Tax - Deferred - Domestic
- (644.00M) (169.00M) (343.00M)
Income Tax - Deferred - Foreign
- 22.00M (42.00M) (131.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
1.53B 1.71B 1.68B 1.42B
Minority Interest Expense
- - - -
-
Net Income
1.53B 1.71B 1.68B 1.42B
Net Income Growth
-6.42% +11.44% -1.58% -15.55%
Net Margin Growth
+7.90% +8.45% +7.68% +7.28%
Extraordinaries & Discontinued Operations
- - (46.00M) (271.00M)
-
Discontinued Operations
- - (46.00M) (271.00M)
-
Net Income After Extraordinaries
1.48B 1.71B 1.68B 1.15B
Preferred Dividends
- - - 60.00M
-
Net Income Available to Common
1.42B 1.71B 1.68B 1.15B
EPS (Basic)
4.9741 5.8841 5.8335 4.1115
EPS (Basic) Growth
-16.07% +18.29% -0.86% -29.52%
Basic Shares Outstanding
286.28M 289.76M 287.65M 278.49M
EPS (Diluted)
4.9377 5.8589 5.8161 4.0902
EPS (Diluted) Growth
-15.99% +18.66% -0.73% -29.67%
Diluted Shares Outstanding
288.39M 291.01M 288.51M 279.94M
EBITDA
4.36B 5.23B 5.69B 5.30B
EBITDA Growth
-5.65% +20.06% +8.85% -6.92%
EBITDA Margin
+22.49% +25.92% +26.07% +27.24%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 219.154
Number of Ratings 19 Current Quarters Estimate 2.379
FY Report Date 12 / 2026 Current Year's Estimate 13.293
Last Quarter’s Earnings 4.15 Median PE on CY Estimate N/A
Year Ago Earnings 12.70 Next Fiscal Year Estimate 14.337
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 12 12 15 13
Mean Estimate 2.38 3.01 13.29 14.34
High Estimates 2.71 3.14 13.80 15.90
Low Estimate 2.34 2.95 13.15 13.80
Coefficient of Variance 4.40 1.67 1.57 3.50

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 8 7 6
OVERWEIGHT 3 3 3
HOLD 7 8 7
UNDERWEIGHT 0 0 1
SELL 1 1 0
MEAN Overweight Overweight Overweight

Insider Actions for Becton Dickinson & Co. - BDX

Date Name Shares Transaction Value
Oct 28, 2026 Michael Feld EVP, Chief Revenue Officer 19,568 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $198.13 per share 3,877,007.84
Mar 18, 2026 Lanesha T. Minnix EVP and General Counsel 7,492 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Dec 3, 2025 Jacqueline Wright Director 180 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Dec 3, 2025 Robert L. Huffines Director 180 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Dec 2, 2025 Bilal Muhsin EVP & President Connected Care 21,751 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Dec 2, 2025 Michael Feld EVP, CRO & Pres. Life Sciences 16,655 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 0.00
Dec 2, 2025 Pavan Kumar Mocherla EVP & President, Greater Asia 5,055 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Dec 2, 2025 David Shan EVP and Chief ISC Officer 8,970 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 0.00
Dec 2, 2025 David Shan EVP and Chief ISC Officer 9,104 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Dec 2, 2025 David Shan EVP and Chief ISC Officer 8,079 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Dec 2, 2025 Christopher J. DelOrefice EVP & Chief Financial Officer 22,982 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 0.00
Dec 2, 2025 Christopher J. DelOrefice EVP & Chief Financial Officer 27,227 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Dec 2, 2025 Richard E. Byrd EVP & President Interventional 15,568 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Dec 2, 2025 Richard E. Byrd EVP & President Interventional 13,183 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Dec 2, 2025 Roland Goette EVP and President, EMEA 17,222 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 0.00
Dec 2, 2025 Roland Goette EVP and President, EMEA 17,360 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Dec 2, 2025 Roland Goette EVP and President, EMEA 16,123 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Dec 2, 2025 Thomas E. Polen Chairman, CEO and President 165,581 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Dec 2, 2025 Thomas E. Polen Chairman, CEO and President 105,471 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 0.00
Dec 2, 2025 Thomas E. Polen Chairman, CEO and President 122,892 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Becton Dickinson & Co. in the News